[A trial of ACNU and radiation therapy with sensitizing agents for malignant gliomas].
Twelve cases of malignant gliomas (anaplastic astrocytoma 4, glioblastoma 8, recurrent 3, primary 9) were treated with ACNU and radiation with sensitizing agents after the surgical removal of the tumor. BUdR, Vidarabine (Ara-A), Aciclovir (ACV) were applied for sensitizing agents. BUdR was administrated intraarterially prior to radiation (380 rad, two times a week), and Ara-A and ACV intravenously during and after the radiation. Total dosage of the radiation was 50-60 Grey for each case. All recurrent and eight primary patients died. The mean survival time of the recurrent patients was 17.7 months, while that of the primary patients was 13.4 months. One of the primary patient was glioblastoma and is still surviving more than 24 months by now. The complete response (CR) rate of the primary tumor patients observed by computerized tomography (CT) scan was 5/9. We can expect the availability of this trial for malignant gliomas because of high CR rate in primary tumor cases.
Kawano
H
H
Department of Neurosurgery, Fukui Medical School, Matsuoka, Japan.
Hayashi
M
M
Satoh
K
K
Ishii
H
H
Nakatsugawa
S
S
Ishii
Y
Y
D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D001973:Bromodeoxyuridine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000009:adverse effects / Q000627:therapeutic use*; D011832:Radiation Injuries; D011838:Radiation-Sensitizing Agents; D011879:Radiotherapy Dosage; D012074:Remission Induction; D014740:Vidarabine / Q000627:therapeutic use
D011838:Radiation-Sensitizing Agents; D015376:Nimustine; D014740:Vidarabine; D001973:Bromodeoxyuridine; D000212:Acyclovir